1. BONE MARROW INVOLVEMENT, BUT NO BLOOD INVOLVEMENT, IMPAIRS SURVIVAL IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: AN ANCILLARY STUDY OF THE REVAIL TRIAL. (12th June 2019) Authors: Lemonnier, F.; Safar, V.; Ferchiou, A.; Cottereau, A.; Bachy, E.; Cartron, G.; Moles‐Moreau, M.; Delmer, A.; Bouabdallah, R.; Voillat, L.; Parrens, M.; Casasnovas, O.; Cacheux, V.; Réguy, C.; Tilly, H.; Meignan, M.; Gaulard, P.; de Leval, L.; Delfau‐Larrue, M.; Haioun, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 278 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE. (23rd June 2022) Authors: Schavgoulidze, A.; Perrot, A.; Cazaubiel, T.; Leleu, X.; Manier, S.; Buisson, L.; Maheo, S.; Do Souto Ferreira, L.; Lannes, R.; Pavageau, L.; Hulin, C.; Marolleau, J.-P.; Voillat, L.; Belhadj, K.; Divoux, M.; Slama, B.; Brechignac, S.; Macro, M.; Stoppa, A.-M.; Sanhes, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 765 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PROGNOSTIC VALUE OF IMMUNOHISTOCHEMICAL MARKERS IN STAGE III/IV CLASSICAL HODGKIN LYMPHOMA TREATED FRONTLINE IN THE LYSA EORTC 20012 RANDOMIZED PROTOCOL. (June 2017) Authors: Canioni, D.; Brice, P.; Bologna, S.; Voillat, L.; Gabarre, J.; Casasnovas, O.; Devidas, A.; Coiffier, B.; Aoudjhane, A.; Audouy, B.; Andre, M.; Fortpied, C.; Carde, P.; Mounier, N.; Briere, J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 162 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗